Nonrenal Indications for Continuous Arteriovenous Hemofiltration.
- Author:
In Sang LEE
1
;
Jung Hyen PARK
;
In Tae LEE
;
Chi Hak KIM
Author Information
1. Department of Internal Medicine, Dae Dong Hospital, Pusan, Korea.
- Publication Type:Original Article
- Keywords:
CAVH;
Nonrenal Indications
- MeSH:
Ascites;
Cholangitis;
Creatinine;
Diabetic Ketoacidosis;
Edema;
Female;
Hemofiltration*;
Hemorrhage;
Hepatic Encephalopathy;
Humans;
Hypotension;
Liver Cirrhosis;
Male;
Pulmonary Edema;
Renal Insufficiency;
Retrospective Studies;
Sepsis;
Shock, Septic;
Sodium;
Thrombocytopenia
- From:Korean Journal of Nephrology
1998;17(3):476-482
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Continuous arteriovenous hemofiltration(CAVH) is used to treat hemodynamically unstable patients with renal failure, refractory ascites and edema, sepsis, or ARDS patients. Patients received CAVH during a 3-year-period from March 1994 to February 1997. Their clinical findings were analyzed retrospectively, and the results were as follows; They were 6 men and 3 women from 28 to 62 years. 3 patients had ARDS, 2 patients had CHF. The remainder had SLE, liver cirrhosis, septic shock with cholangitis, diabetic ketoacidosis with pulmonary edema. The duration of treatment ranged from 30 to 50 hours, with a mean of 41.6+/-6.9 hours. The total fluid repalcement was 22.4+/-1.7L and the mean fluid loss was 3.9+/-2.6L. Changes in serum BUN, creatinine, sodium, potasium before and after treatment were not significantly diffrent. The complication of CAVH is clotting of hemofilter, hypotension, bleeding, and mild thrombocytopenia. 2 of 3 ARDS patients expired during CAVH, liver cirrhosis patient expired later due to hepatic encephalopathy, and, finally 6 patients discharged with improved conditions. In conclusion, CAVH, a safe and effective therapy in hemodynamically unstable patients with renal failure, refractory ascites and edema, sepsis, or ARDS patients.
